vs
Side-by-side financial comparison of Blaize Holdings, Inc. (BZAI) and Karyopharm Therapeutics Inc. (KPTI). Click either name above to swap in a different company.
Karyopharm Therapeutics Inc. is the larger business by last-quarter revenue ($34.1M vs $23.8M, roughly 1.4× Blaize Holdings, Inc.). Blaize Holdings, Inc. runs the higher net margin — -13.9% vs -299.9%, a 286.0% gap on every dollar of revenue. On growth, Blaize Holdings, Inc. posted the faster year-over-year revenue change (2377500.0% vs 11.6%).
Blaize Holdings, Inc. is a technology company specializing in edge artificial intelligence computing solutions. It designs energy-efficient AI processors, low-latency inference software stacks, and end-to-end edge AI development tools, serving key segments including autonomous driving, industrial automation, smart cities, and edge healthcare monitoring.
BZAI vs KPTI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $23.8M | $34.1M |
| Net Profit | $-3.3M | $-102.2M |
| Gross Margin | 10.8% | — |
| Operating Margin | -89.8% | -52.4% |
| Net Margin | -13.9% | -299.9% |
| Revenue YoY | 2377500.0% | 11.6% |
| Net Profit YoY | 50.7% | -232.0% |
| EPS (diluted) | $0.16 | $-7.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $23.8M | $34.1M | ||
| Q3 25 | $11.9M | $44.0M | ||
| Q2 25 | — | $37.9M | ||
| Q1 25 | — | $30.0M | ||
| Q4 24 | — | $30.5M | ||
| Q3 24 | — | $38.8M | ||
| Q2 24 | — | $42.8M | ||
| Q1 24 | — | $33.1M |
| Q4 25 | $-3.3M | $-102.2M | ||
| Q3 25 | $-26.3M | $-33.1M | ||
| Q2 25 | — | $-37.3M | ||
| Q1 25 | — | $-23.5M | ||
| Q4 24 | — | $-30.8M | ||
| Q3 24 | — | $-32.1M | ||
| Q2 24 | — | $23.8M | ||
| Q1 24 | — | $-37.4M |
| Q4 25 | 10.8% | — | ||
| Q3 25 | 15.0% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -89.8% | -52.4% | ||
| Q3 25 | -190.3% | -34.6% | ||
| Q2 25 | — | -64.3% | ||
| Q1 25 | — | -110.8% | ||
| Q4 24 | — | -102.4% | ||
| Q3 24 | — | -67.8% | ||
| Q2 24 | — | -65.7% | ||
| Q1 24 | — | -101.9% |
| Q4 25 | -13.9% | -299.9% | ||
| Q3 25 | -221.3% | -75.2% | ||
| Q2 25 | — | -98.2% | ||
| Q1 25 | — | -78.2% | ||
| Q4 24 | — | -100.8% | ||
| Q3 24 | — | -82.7% | ||
| Q2 24 | — | 55.6% | ||
| Q1 24 | — | -112.8% |
| Q4 25 | $0.16 | $-7.02 | ||
| Q3 25 | $-0.25 | $-3.82 | ||
| Q2 25 | — | $-4.32 | ||
| Q1 25 | — | $-2.77 | ||
| Q4 24 | — | $-2.33 | ||
| Q3 24 | — | $-3.85 | ||
| Q2 24 | — | $-2.97 | ||
| Q1 24 | — | $-4.85 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $45.8M | $60.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $39.0M | $-292.9M |
| Total Assets | $102.2M | $108.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.8M | $60.5M | ||
| Q3 25 | $24.0M | $37.7M | ||
| Q2 25 | — | $38.7M | ||
| Q1 25 | — | $38.8M | ||
| Q4 24 | — | $62.5M | ||
| Q3 24 | — | $72.8M | ||
| Q2 24 | — | $84.8M | ||
| Q1 24 | — | $30.6M |
| Q4 25 | $39.0M | $-292.9M | ||
| Q3 25 | $1.3M | $-269.3M | ||
| Q2 25 | — | $-238.9M | ||
| Q1 25 | — | $-205.9M | ||
| Q4 24 | — | $-186.0M | ||
| Q3 24 | — | $-159.6M | ||
| Q2 24 | — | $-132.1M | ||
| Q1 24 | — | $-169.0M |
| Q4 25 | $102.2M | $108.4M | ||
| Q3 25 | $60.9M | $96.2M | ||
| Q2 25 | — | $104.9M | ||
| Q1 25 | — | $127.7M | ||
| Q4 24 | — | $164.4M | ||
| Q3 24 | — | $189.5M | ||
| Q2 24 | — | $214.0M | ||
| Q1 24 | — | $204.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-16.5M | $-11.8M |
| Free Cash FlowOCF − Capex | $-16.5M | — |
| FCF MarginFCF / Revenue | -69.6% | — |
| Capex IntensityCapex / Revenue | 0.3% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-16.5M | $-11.8M | ||
| Q3 25 | $-24.9M | $-5.9M | ||
| Q2 25 | — | $-18.7M | ||
| Q1 25 | — | $-39.0M | ||
| Q4 24 | — | $-25.8M | ||
| Q3 24 | — | $-19.5M | ||
| Q2 24 | — | $-38.5M | ||
| Q1 24 | — | $-43.7M |
| Q4 25 | $-16.5M | — | ||
| Q3 25 | $-24.9M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-25.9M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-43.9M |
| Q4 25 | -69.6% | — | ||
| Q3 25 | -210.2% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -84.7% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -132.6% |
| Q4 25 | 0.3% | 0.0% | ||
| Q3 25 | 0.2% | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -1.62× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BZAI
Segment breakdown not available.
KPTI
| Products | $32.1M | 94% |
| License And Other | $2.0M | 6% |
